145 related articles for article (PubMed ID: 31506287)
41. Familial MPN Predisposition.
Tashi T; Swierczek S; Prchal JT
Curr Hematol Malig Rep; 2017 Oct; 12(5):442-447. PubMed ID: 29027642
[TBL] [Abstract][Full Text] [Related]
42. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
43. Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease.
Au WY; Leung R; Mok T; Fung A; Liang R
Ann Hematol; 2008 Nov; 87(11):931-2. PubMed ID: 18521603
[No Abstract] [Full Text] [Related]
44. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
45. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
[TBL] [Abstract][Full Text] [Related]
46. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
[TBL] [Abstract][Full Text] [Related]
47. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
48. Advances in inherited cancers: Introduction.
Stoffel EM; Cooney KA
Semin Oncol; 2016 Oct; 43(5):527. PubMed ID: 27899182
[No Abstract] [Full Text] [Related]
49. Molecular genetic biomarkers in myeloid malignancies.
Matynia AP; Szankasi P; Shen W; Kelley TW
Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
[TBL] [Abstract][Full Text] [Related]
50. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
Owen C
Leuk Res; 2010 Feb; 34(2):141-2. PubMed ID: 19695705
[No Abstract] [Full Text] [Related]
51. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
52. Epimutations and cancer predisposition: importance and mechanisms.
Hesson LB; Hitchins MP; Ward RL
Curr Opin Genet Dev; 2010 Jun; 20(3):290-8. PubMed ID: 20359882
[TBL] [Abstract][Full Text] [Related]
53. Genetic studies in the evaluation of myeloproliferative neoplasms.
Caponetti GC; Bagg A
Semin Hematol; 2019 Jan; 56(1):7-14. PubMed ID: 30573049
[TBL] [Abstract][Full Text] [Related]
54. Identifying patients with genetic predisposition to acute myeloid leukemia.
Obrochta E; Godley LA
Best Pract Res Clin Haematol; 2018 Dec; 31(4):373-378. PubMed ID: 30466750
[TBL] [Abstract][Full Text] [Related]
55. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
[TBL] [Abstract][Full Text] [Related]
56. Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm.
Rumi E; Casetti I; Pietra D; Elena C; Ambaglio I; Pascutto C; Passamonti F; Cazzola M;
Am J Hematol; 2012 Jan; 87(1):129-30. PubMed ID: 22038760
[No Abstract] [Full Text] [Related]
57. MicroRNAs in myeloid malignancies.
Gordon JE; Wong JJ; Rasko JE
Br J Haematol; 2013 Jul; 162(2):162-76. PubMed ID: 23679825
[TBL] [Abstract][Full Text] [Related]
58. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.
Adélaïde J; Gelsi-Boyer V; Rocquain J; Carbuccia N; Birnbaum DJ; Finetti P; Bertucci F; Mozziconacci MJ; Vey N; Birnbaum D; Chaffanet M
Leukemia; 2010 Aug; 24(8):1539-41. PubMed ID: 20555362
[No Abstract] [Full Text] [Related]
59. DNMT3A mutations in myeloproliferative neoplasms.
Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
[No Abstract] [Full Text] [Related]
60. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
